Therapy Detail

Therapy Name KRAS mutant-specific TIL
Therapy Description

KRAS-mutant specific autologous tumor-infiltrating cells are patient-derived tumor-infiltrating cells that contain cytotoxic T-cells that target KRAS-mutant tumor cells, which upon expansion and infusion potentially induce regression of KRAS-mutant tumors (PMID: 27959684).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
KRAS mutant-specific TIL KRAS-mutant specific autologous tumor-infiltrating cells KRAS-mutant specific autologous tumor-infiltrating cells are patient-derived tumor-infiltrating cells that contain cytotoxic T-cells that target KRAS-mutant tumor cells, which upon expansion and infusion potentially induce regression of KRAS-mutant tumors (PMID: 27959684).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS G12D colorectal cancer sensitive KRAS mutant-specific TIL Clinical Study Actionable In a clinical case study, a patient with metastatic colorectal cancer harboring KRAS G12D demonstrated regression of metastatic lung lesions and a partial response for 9 months following infusion of autologous tumor-infiltrating lymphocytes containing cytotoxic T-cells that specifically recognize KRAS G12D (PMID: 27959684). 27959684
Clinical Trial Phase Therapies Title Recruitment Status